专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR1020120134938A ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도 有权
标题翻译： C-MET定位具有HGF活性的全身激动人体抗体及其用途
公开(公告)号：KR1020120134938A
公开(公告)日：2012-12-12
申请号：KR1020110054177
申请日：2011-06-03
申请人： 한국생명공학연구원 , 주식회사 와이바이오로직스
发明人： 박영우 , 조기원 , 박찬웅 , 유석호 , 장명희 , 김혜난 , 윤선하 , 조규원 , 박미라
IPC分类号： C07K16/22 , C12N15/13 , A61K39/395 , A61P25/28
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/622 , C07K2317/75 , C07K2317/92 , C07K2317/94
摘要： PURPOSE: A human antibody which is derived from human body and specifically binds to c-Met is provided to treat neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney, liver, lung injury, and ulcerative wound which are cured by HGF or c-Met activation. CONSTITUTION: A human antibody contains a complementarity determining region (CDR) and framework region(FR) which are derived from human and specifically binds to c-Met. The human antibody contains: a heavy chain variable region containing heavy chain CDR1 of sequence number 1, heavy chain CDR2 of sequence number 2, and heavy chain CDR3 of sequence number 3; and a light chain variable region containing light chain CDR1 of sequence number 4, light chain CDR2 of sequence number 5, and light chain CDR3 of sequence number 6. The antibody contains a heavy chain variable region amino acid of sequence number 7 and a light chain variable region amino acid of sequence number 8. The human antibody is glycosylated or/and PEGylated. A composition for wound healing contains the human antibody as an active ingredient and pharmaceutically acceptable carrier. A composition for treating neurodegenerative diseases contains the human antibody as an active ingredient and pharmaceutically acceptable carrier.
摘要翻译：目的：提供从人体衍生并特异性结合c-Met的人类抗体，用于治疗由HGF或其他物质固化的神经元梗死，进行性肾病，肝硬化，肺纤维化，肾脏，肝脏，肺损伤和溃疡性伤口 c-Met激活。构成：人抗体含有衍生自人体并且特异性结合c-Met的互补决定区（CDR）和框架区（FR）。人抗体包含：含有序列号1的重链CDR1，序列号2的重链CDR2和序列号3的重链CDR3的重链可变区; 和含有序列号4的轻链CDR1，序列号5的轻链CDR2和序列号6的轻链CDR3的轻链可变区。抗体含有序列号7的重链可变区氨基酸和轻链可变区氨基酸序列号8.人抗体是糖基化的或/和聚乙二醇化的。用于伤口愈合的组合物包含人抗体作为活性成分和药学上可接受的载体。用于治疗神经变性疾病的组合物含有人抗体作为活性成分和药学上可接受的载体。

2. 发明授权

KR101444837B1 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도 有权
标题翻译： c-Met靶向具有HGF活性的完全激动剂人抗体及其用途
公开(公告)号：KR101444837B1
公开(公告)日：2014-09-30
申请号：KR1020110054177
申请日：2011-06-03
申请人： 한국생명공학연구원 , 주식회사 와이바이오로직스
发明人： 박영우 , 조기원 , 박찬웅 , 유석호 , 장명희 , 김혜난 , 윤선하 , 조규원 , 박미라
IPC分类号： C07K16/22 , C12N15/13 , A61K39/395 , A61P25/28
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/622 , C07K2317/75 , C07K2317/92 , C07K2317/94
摘要： 본 발명은 c-Met에 특이적으로 결합하는 인간으로부터 유래된 상보성 결정영역(CDR)과 프레임 워크 영역(FR)으로 구성된 인간항체, 상기 인간항체를 코딩하는 폴리뉴클레오티드, 상기 폴리뉴클레오티드를 포함하는 발현 벡터, 상기 발현 벡터로 형질전환된 형질전환체, 상기 형질전환체를 배양하여 상기 인간항체 B7을 제조하는 방법, 상기 인간항체를 유효성분으로 포함하는 상처치료용 조성물, 상기 인간항체를 유효성분으로 포함하는 세포재생용 조성물 및 상기 인간항체에 약물이 결합된 약물 결합체에 관한 것이다. 본 발명의 c-Met에 특이적인 인간항체는 HGF의 mimic으로 작용하여 상처치료용 조성물로 사용될 수 있으며, 상기 HGF나 c-Met의 활성화로 치유되는 다양한 질환(Neuronal Infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, Kidney, Liver, Lung injury, Ulcerative wound)에 대한 치료 및 예후 판정 등에 널리 활용될 수 있을 것이다.

3. 发明授权

KR101004362B1 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제 有权
标题翻译： TNF-α和TWEAK联合拮抗剂预防和治疗自身免疫性疾病
公开(公告)号：KR101004362B1
公开(公告)日：2010-12-28
申请号：KR1020100024699
申请日：2010-03-19
申请人： 한국생명공학연구원 , 가톨릭대학교 산학협력단
发明人： 박영우 , 조기원 , 유석호 , 유정 , 김동진 , 윤선하 , 송은정 , 이은경 , 오진미 , 조규원 , 조미라 , 김호연 , 박미경 , 오혜좌 , 박진실 , 우윤주
IPC分类号： C07K19/00 , C12N15/62 , C12N15/63 , A61P37/00
CPC分类号： C07K14/525 , C07K14/70575 , C07K2319/32 , Y10S514/814 , Y10S514/885 , Y10S514/886 , Y10S514/903
摘要： PURPOSE: A TNFR2-TWEAKR fusion protein is provided to ensure antagonistic function to TNFR2 and TWEAK which is a cause of autoimmune arthritis and to reduce IL-17 secretion. CONSTITUTION: A composition for preventing and treating autoimmune disease contains fusion protein of a fragment having an extracellular region of TNFR2(Tumor necrosis factor receptor type 2) or TNFR2 and a fragment having an extracellular region of TWEAKR(TNF-related weak inducer of apoptosis receptor) protein or TWEAKR as an active ingredient. The extracellular region fragment of TNFR2 has a polypeptide having an amino acid sequence of sequence number 2. The fusion protein has an amino acid sequence of sequence number 1.
摘要翻译：目的：提供TNFR2-TWEAKR融合蛋白，以确保TNFR2和TWEAK的拮抗作用，这是导致自身免疫性关节炎和降低IL-17分泌的原因。构成：用于预防和治疗自身免疫性疾病的组合物含有具有TNFR2细胞外区域（2型肿瘤坏死因子受体）或TNFR2的片段的融合蛋白和具有TWEAKR胞外区域的片段（TNF相关的凋亡受体弱诱导剂）蛋白质或TWEAKR作为活性成分。 TNFR2的细胞外区片段具有序列号为2的氨基酸序列的多肽。融合蛋白具有序列号1的氨基酸序列。

4. 发明公开

KR1020120100027A 엔도사이토시스 모티프 및 단백질 도입 도메인을 포함하는 암 예방 또는 치료용 약학적 조성물 审中-实审
标题翻译：用于预防或治疗包含内源性MOTIF和蛋白质转染域的癌症的药物组合物
公开(公告)号：KR1020120100027A
公开(公告)日：2012-09-12
申请号：KR1020110018628
申请日：2011-03-02
申请人： 한국생명공학연구원
发明人： 박영우 , 조기원 , 조규원 , 박지현 , 현순실 , 박윤정
IPC分类号： C07K7/08 , C07K14/475 , A61K38/00 , A61K38/10 , A61K38/18
CPC分类号： C07K7/08 , A61K38/00 , C07K14/00 , C07K14/4753 , C07K2319/10 , A61K38/10 , A61K38/18
摘要： PURPOSE: A pharmaceutical composition for cancer prevention or treatment including endocytic motif and protein introduction domain is provided to specifically inhibit endocytosis of c-Met by polypeptide in order to effectively inhibits HGF/c-Met signal transmission path and inhibit transition, infiltration, vascularization and growth of cancer. CONSTITUTION: A pharmaceutical composition for cancer prevention or treatment includes endocytic motif which is represented as amino acid sequence having the sequence number 1(SEQ ID NO:1). The motif is imported inside cells by clathrin mediated endocytosis. The motif is c-Met, phosphorylated c-Met, or c-Met combined with HGF(hepatocyte growth factor). The motif inhibits self - phosphorylation of c-Met by HGF. The Pharmaceutical composition for preventing or treating cancers includes motif as an active ingredient. A fused polypeptide is endocytotic motif-C terminal represented by equation 1: N-terminal-protein transduction domain-amino acid sequence having the sequence number 1 or endocytic motif - protein transduction domain -C terminal represented by equation 2: N- terminal-amino acid sequence having the sequence number 1. The protein transduction domain is Tat of HIV(human immunodeficiency virus); VP22 of HSP(herpes simplex virus); Antp of pomace fly; Mph-1; Sim-2; R7; Pep-1; or Pep-2.
摘要翻译：目的：提供一种用于癌症预防或治疗的药物组合物，包括内吞基序和蛋白质引入结构域，以特异性抑制多肽对c-Met的内吞作用，以有效抑制HGF / c-Met信号传递途径并抑制转化，浸润，血管化和癌症的增长。构成：用于癌症预防或治疗的药物组合物包括表示为具有序列号1（SEQ ID NO：1）的氨基酸序列的内吞基序。该基序通过网格蛋白介导的内吞作用进入细胞内。该基序是c-Met，磷酸化c-Met或c-Met与HGF（肝细胞生长因子）组合。该基序抑制HGF自身磷酸化c-Met。用于预防或治疗癌症的药物组合物包括作为活性成分的基序。融合多肽是由等式1表示的内吞基序-C末端：具有序列号1的N末端蛋白转导结构域 - 氨基酸序列或由等式2表示的内吞基序 - 蛋白转导结构域-C末端：N-末端氨基具有序列号1的酸序列。蛋白转导结构域是HIV的Tat（人免疫缺陷病毒）; HSP（单纯疱疹病毒）VP22; 荞麦飞 MPH-1; SIM-2; R7; PEP-1; 或Pep-2。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式